Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Stony Brook University Researchers Develop Groundbreaking New Graphene-Based MRI Contrast Agent

Balaji Sitharaman, PhD
Balaji Sitharaman, PhD

Abstract:
Dr. Balaji Sitharaman, PhD, an Assistant Professor in the Department of Biomedical Engineering at Stony Brook University, and a team of researchers developed a new, highly efficacious, potentially safer and more cost effective nanoparticle-based MRI (magnetic resonance imaging) contrast agent for improved disease diagnosis and detection. The most recent findings are discussed in detail in his team's research paper "Physicochemical characterization, and relaxometry studies of micro-graphite oxide, graphene nanoplatelets, and nanoribbons," published in the June 7 edition of the journal PLoS ONE.

Stony Brook University Researchers Develop Groundbreaking New Graphene-Based MRI Contrast Agent

Stony Brook, NY | Posted on June 7th, 2012

The MRI, the technology for which was invented at Stony Brook University by Professor Paul Lauterbur, is one of the most powerful and central techniques in diagnostic medicine and biomedical research used primarily to render anatomical details for improved diagnosis of many pathologies and diseases. Currently, most MRI procedures use gadolinium-based contrast agents to improve the visibility and definition of disease detection. However, recent studies have shown harmful side effects, such as nephrogenic systemic fibrosis, stemming from the use of this contrast agent in some patients, forcing the Food and Drug Administration (FDA) to place restrictions on the clinical use of gadolinium. Further, most MRI contrast agents are not suitable for extended-residence-intravascular (blood pool), or tissue (organ)-specific imaging, and do not allow molecular imaging.

To address the need for an MRI contrast agent that demonstrates greater effectiveness and lower toxicity, Dr. Sitharaman developed a novel high-performance graphene-based contrast agent that may replace the gadolinium-based agent which is widely used by physicians today. "A graphene-based contrast agent can allow the same clinical MRI performance at substantially lower dosages," said Dr. Sitharaman. The project is a Wallace H. Coulter Foundation Translational Research Award winner and the recipient of a two-year translational grant to study preclinical safety and efficacy.

"The technology will lower health care costs by reducing the cost per dose as well as the number of doses required," noted Dr. Sitharaman. "Further, since this new MRI contrast agent will substantially improve disease detection by increasing sensitivity and diagnostic confidence, it will enable earlier treatment for many diseases, which is less expensive, and of course more effective for diseases such as cancer."

The new graphene-based imaging contrast agent is also the focus of Dr. Sitharaman's start-up company, Theragnostic Technologies, Inc., which was incorporated in early 2012. The ongoing development of this technology is supported by industry expert and business advisor, Shahram Hejazi, and clinical experts Kenneth Shroyer, MD, PhD, Professor and Chair, Department of Pathology, Stony Brook University, and William Moore, MD, Chief of Thoracic Imaging, and Assistant Professor, Department of Radiology, Stony Brook University. Co-authors of the article include Department of Biomedical Engineering research assistants Bhavna Paratala, Barry Jacobson and Shruti Kanakia; and Leonard Deepak Francis from the International Iberian Nanotechnology Laboratory in Portugal.

Dr. Sitharaman's research team focuses their interests at the interface of bionanotechnology, regenerative and molecular medicine. They seek to "synergize" the advancements in each of these fields to develop a dynamic research program that tackles problems related to the diagnosis and treatment of disease and tissue regeneration. Dr. Sitharaman received his BS with Honors from the Indian Institute of Technology and his PhD from Rice University, where he also completed his postdoctoral work as a J. Evans Attwell-Welch Postdoctoral Fellowship recipient.

####

For more information, please click here

Contacts:
Stony Brook University Office of Media Relations
631.632.6310

Copyright © Newswise

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Super sensitive measurement of magnetic fields March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Graphene

'Atomic chicken-wire' is key to faster DNA sequencing March 30th, 2015

Graphene reduces wear of alumina ceramic March 26th, 2015

Square ice filling for a graphene sandwich March 26th, 2015

Imaging

'Atomic chicken-wire' is key to faster DNA sequencing March 30th, 2015

FEI Technology Award of the German Neuroscience Society Goes to Benjamin Judkewitz of the University of Berlin: Bi-annual award honors excellence in brain research during the German Neuroscience Society’s Annual Meeting, held 18-21 March 2015 March 26th, 2015

Nanomedicine

Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015

Nanomedicine shines light on combined force of nanomedicine and regenerative medicine March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Discoveries

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Super sensitive measurement of magnetic fields March 31st, 2015

From tobacco to cyberwood March 31st, 2015

Announcements

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Super sensitive measurement of magnetic fields March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE